KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $22.9 million.

  • Emergent BioSolutions' Capital Expenditures fell 41.38% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 64.42%. This contributed to the annual value of $22.9 million for FY2024, which is 55.62% down from last year.
  • As of FY2024, Emergent BioSolutions' Capital Expenditures stood at $22.9 million, which was down 55.62% from $51.6 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Capital Expenditures registered a high of $243.7 million during FY2022, and its lowest value of $22.9 million during FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $51.6 million (2023), whereas its average is $106.1 million.
  • In the last 5 years, Emergent BioSolutions' Capital Expenditures skyrocketed by 63.29% in 2020 and then plummeted by 78.83% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Capital Expenditures (Yearly) stood at $141.9 million in 2020, then surged by 57.93% to $224.1 million in 2021, then increased by 8.75% to $243.7 million in 2022, then plummeted by 78.83% to $51.6 million in 2023, then slumped by 55.62% to $22.9 million in 2024.